Ofir Cohen

Ofir Cohen

Harvard University

H-index: 33

North America-United States

About Ofir Cohen

Ofir Cohen, With an exceptional h-index of 33 and a recent h-index of 28 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Molecular Evolution, Cancer Genomics, Drug Resistance, Metastatic Breast Cancer, Medical Informatics.

His recent articles reflect a diverse array of research interests and contributions to the field:

Author Correction: Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments

Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer

Mutated HRAS activates YAP1–AXL signaling to drive metastasis of head and neck cancer

SlideCNA: Spatial copy number alteration detection from Slide-seq-like spatial transcriptomics data

Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

Ofir Cohen Information

University

Position

Broad Institute

Citations(all)

9836

Citations(since 2020)

8104

Cited By

4580

hIndex(all)

33

hIndex(since 2020)

28

i10Index(all)

42

i10Index(since 2020)

41

Email

University Profile Page

Google Scholar

Ofir Cohen Skills & Research Interests

Molecular Evolution

Cancer Genomics

Drug Resistance

Metastatic Breast Cancer

Medical Informatics

Top articles of Ofir Cohen

Author Correction: Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments

Nature Cell Biology

2024/3/5

Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

Cancer Research

2023/3/1

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Cell Reports

2023/8/29

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer

Science advances

2023/5/26

Ofir Cohen
Ofir Cohen

H-Index: 21

Mutated HRAS activates YAP1–AXL signaling to drive metastasis of head and neck cancer

Cancer research

2023/4/4

Ofir Cohen
Ofir Cohen

H-Index: 21

SlideCNA: Spatial copy number alteration detection from Slide-seq-like spatial transcriptomics data

bioRxiv

2022/11/27

Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit

JCO Precision Oncology

2022/7

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

Nature Communications

2022/4/19

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Cancer Research

2022/2/15

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Cancer Research

2021/2/15

Abstract OT-18-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research

Cancer Research

2021/2/15

Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)

Cancer Research

2021/2/15

Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+ …

Cancer Research

2020/2/15

Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases

Nature Structural & Molecular Biology

2020/1

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

Clinical Cancer Research

2020/11/15

Abstract B23: Genomic sequencing of metastatic hormone-receptor positive breast cancer implicates AKT1 in driving resistance to cyclin-dependent kinase 4/6 inhibitors

Molecular Cancer Research

2020/10/1

Ofir Cohen
Ofir Cohen

H-Index: 21

Nikhil Wagle
Nikhil Wagle

H-Index: 42

See List of Professors in Ofir Cohen University(Harvard University)